Exploristics signs collaboration agreement with Galapagos

Exploristics signs collaboration agreement with Galapagos

Exploristics signs collaboration agreement with Galapagos 260 200 Exploristics

Galapagos

 
Exploristics signs collaboration agreement with Galapagos to embed study simulation into clinical development with innovative software platform KerusCloud.

Exploristics is pleased to announce today a collaboration with Galapagos using Exploristics’ innovative new software platform KerusCloud to establish a more efficient data-driven approach to study design and protocol development within GLPG’s clinical development programs.  The project will use the KerusCloud platform to embed study simulation into normal working practice, creating a bespoke GLPG way to reduce the risks, costs and duration of clinical development programs.

CEO, Aiden Flynn, said “We are delighted that Galapagos have chosen to work with us as they are key innovators in the sector with a keen awareness of the benefits of adopting new technologies early to keep their clinical development programmes at the cutting edge. I believe that with Exploristics’ new KerusCloud simulation software and wraparound services, Galapagos will be well-placed to exploit the unique data-driven insights these can deliver to take their drug development programmes to the next level.

Claus Andersen, Team Leader Statistical Modelling and Data Science at GLPG, said “We are looking very much forward to extending our modelling capabilities for virtual trials with Exploristics. Their strong experience and knowhow will help us be successful.”.

About KerusCloud

KerusCloud is a uniquely powerful study simulation software platform that ensures clinical studies are suitably designed statistically from the outset to maximise their chances of success. To do this, KerusCloud creates highly realistic synthetic data sets (virtual populations) which are then used as a basis for generating thousands of study simulations that accurately mimic the complexity of real clinical studies. This allows researchers to evaluate the performance of a wide variety of study design and analysis options comprehensively in silico, in minutes and choose the best options for real studies, first time. For more information about KerusCloud, visit https://exploristics.com/kerus-cloud/.

About Exploristics

Exploristics is an enabling technology company that transforms clinical development for life science organisations with unique proprietary software and biostatistics services for planning, designing and analysing clinical studies. For more information about Exploristics, visit www.exploristics.com.

About Galapagos

Galapagos (GLPG) is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action.  GLPG is progressing one of the largest pipelines in biotech, with small molecule programs addressing inflammation, fibrosis, and other diseases.  For more information on Galapagos, visit https://www.glpg.com.

    Learn how KerusCloud helped provide evidence which was used to support raising US$30 million in a subsequent financing round.

    X